EUVIMEDEUVIMED entdecken
KommentarOpen Access

Associations Between Prenatal Cannabis Use and Maternal Health Outcomes

Jamie O Lo, Catherine Y Spong

JAMA Internal Medicine · 2024

DOI: 10.1001/jamainternmed.2024.3276 ↗

Kurz gefasst

Kommentar in der Zeitschrift JAMA Internal Medicine, 2024. Verfasst von Jamie O Lo und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland. Hauptthemen laut MEDLINE: Prenatal Exposure Delayed Effects. Die Arbeit nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Comment and ResponseWith the legalization of cannabis in many states, the impact on pregnant individuals is unclear.Young-Wolff and colleagues 1 examine the association between prenatal cannabis use and maternal health outcomes.In a population-based retrospective cohort study over an eight-year period (2011-2019) using data from the Kaiser Permanente Northern California system prenatal cannabis use was defined as any self-reported use during early pregnancy or a positive toxicology test based on universal screening when establishing prenatal care.They examined outcomes of gestational hypertension, preeclampsia, eclampsia, gestational diabetes, gestational weight gain above and below guidelines, placenta previa, placental abruption, placenta accreta, and severe maternal morbidity.Of 316,722 pregnancies, 6.7% screen positive for prenatal cannabis use, 2.9% positive by self-report, 5.3% by toxicology testing, and 1.8% by both.Prenatal cannabis use was associated with a greater risk of gestational hypertension (aRR=1.17,95% CI: 1.13-1.22),preeclampsia (aRR=1.13,95%CI: 1.05-1.22),weight gain below (aRR=1.05,95%CI: 1.01-1.08)and above (aRR=1.09,95%CI: 1.08-1.10)guidelines, and placental abruption (aRR=1.2,95%CI: 1.05-1.36),but inversely associated with gestational diabetes (aRR=0.89,95%CI: 0.85-0.94).The most common pattern of cannabis use was monthly or less (1.5%), followed by weekly (0.7%) and daily (0.6%).Over the past two decades, the potency and prevalence of prenatal cannabis use has more than doubled, in part due to changing legalization patterns leading to greater availability and perceived safety. 2 Cannabis is now the most widely used federally illegal drug in pregnancy.2 Many use cannabis to alleviate symptoms of nausea, insomnia, pain and

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prenatal Exposure Delayed EffectsHumansPregnancyFemaleAdultMarijuana UsePregnancy OutcomeMaternal HealthCannabis

Autor:innen und Institutionen

  • Department of Obstetrics and Gynecology, Oregon Health & Science University, Portland.
  • Division of Reproductive and Developmental Science, Oregon National Primate Research Center, Beaverton.
  • Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center, Dallas.
  • Parkland Health, Dallas, Texas.

Förderung

  • NIDA NIH HHS

Zitieren

APA

Lo, J. O., & Spong, C. Y. (2024). Associations Between Prenatal Cannabis Use and Maternal Health Outcomes. JAMA Internal Medicine. https://doi.org/10.1001/jamainternmed.2024.3276

Vancouver

Lo JO, Spong CY. Associations Between Prenatal Cannabis Use and Maternal Health Outcomes. JAMA Internal Medicine. 2024. doi:10.1001/jamainternmed.2024.3276

BibTeX
@article{Lo2024,
  author = {Lo, Jamie O and Spong, Catherine Y},
  title = {Associations Between Prenatal Cannabis Use and Maternal Health Outcomes},
  journal = {JAMA Internal Medicine},
  year = {2024},
  doi = {10.1001/jamainternmed.2024.3276}
}
Kostenlos starten →